Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies, announced its partnership with Graticule, an on-demand, advanced real-world data and advisory services provider. The two companies are designing research algorithms and real-world data services to better identify and prioritize patients for clinical trials...
Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, announced that it has entered into a strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets.
"Isomorphic Labs and Novartis hold a shared purpose to reimagine...
Quris-AI, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, announced the addition of Michel Vounatsos, former CEO of Biogen, to its Board of Directors, and the appointment of Yossi Ben Amram, former Merck & Co., Inc. (MSD) Regional President, as President of Quris-AI.
“Adding accomplished pharmaceutical leaders such as Yossi...
Chicago-based Evozyne announced Marc Yoskowitz as CEO of the generative AI-driven biotech.
Yoskowitz, most recently chief strategy officer and executive vice president, life sciences, at Tempus AI, will further develop the company’s strategy, focusing its generative AI platform on drug discovery in areas of high unmet patient need. Yoskowitz has...
Nanotronics, the Industrial AI company, announced a new strategic partnership with OrbiMed, a leading global life sciences investment firm. As part of the transaction, OrbiMed is investing in Nanotronics’ proprietary technology to advance quality control and precision manufacturing across the healthcare and biotech industries.
“AI is redrawing the healthcare landscape...
Swoop, the leading provider of custom direct to consumer (DTC) and healthcare provider (HCP) audiences, today launched its portfolio of predictive AI targeting to help pharmaceutical and life sciences advertisers proactively engage audiences at critical decision points in the diagnosis and treatment journey. Building on its predictive AI adherence...
SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine precision medicine for cancer, announced today it has entered into a strategic collaboration agreement with Mayo Clinic for the development of novel digital precision medicine solutions for breast cancer patients.
The...
Pan-cancer study showed MTM/mL dynamics were more predictive of therapy response than mVAF dynamics, with an observed hazard ratio nearly 2x higher
Natera, Inc., a global leader in cell-free DNA testing, announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter (MTM/mL) against mean...
The collaboration seeks to produce novel off-the-shelf TCR-based bispecific molecules designed to overcome current limitations in cell therapy approaches against solid tumors
ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, announced a partnership with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and...
Fauna Bio, a biotechnology company improving human health by leveraging animal genomics, announced a multi-year agreement with Eli Lilly and Company to apply Fauna's Convergence™ artificial intelligence (AI) platform to support preclinical drug discovery efforts in obesity. The two teams will collaborate to identify multiple drug targets.
Under the terms...
